Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > BioAlliance Pharma Publishes Its 2008 Financial Calendar and Announces the Opening of Its European Corporate Headquarters

Abstract:
BioAlliance Pharma SA (PARIS:BIO) (Euronext Paris - ticker code BIO) has announced its financial calendar for 2008, which notably includes the publication dates for its revenue statements and half-year & annual accounts, as well as the date of its shareholders' Annual General Meeting:

BioAlliance Pharma Publishes Its 2008 Financial Calendar and Announces the Opening of Its European Corporate Headquarters

PARIS, France | Posted on January 21st, 2008

* January 31 2008 : Publication of the revenue statement for Q4 2007
* February 29 2008 : Publication of the consolidated accounts for 2007. SFAF analyst meeting at the Palais Brongniart
* April 11 2008 : Publication of the French "Document de Référence" for 2007
* April 29 2008 : Annual General Meeting at the Maison de la Chimie
* April 30 2008 : Publication of the revenue statement for Q1 2008
* July 21 2008 : Publication of the revenue statement for Q2 2008
* August 28 2008 : Publication of the consolidated half-year accounts as of June 30 2008. SFAF analyst meeting at the Maison de la Chimie
* October 30 2008 : Publication of the revenue statement for Q3 2008
* January 2009 : Publication of the revenue statement for Q4 2008

Along with other corporate information on BioAlliance Pharma S.A., a regularly updated "investor relations" section is available on the company's website (www.bioalliancepharma.com).

Furthermore, in Q1 2008, BioAlliance Pharma will present its corporate communication program for shareholders and the financial community as a whole.

BioAlliance Pharma expands and is set to open its European corporate headquarters.

BioAlliance Pharma will move into new premises in February 2008.

The new corporate headquarters (located at 49, boulevard du Général Martial Valin, in Paris' 15th Arrondissement - just down the street from its current offices) will more than double the available floor space and will enable the company to bring together its entire staff onto a single site.

"The opening of our European corporate HQ represents another important milestone and testifies to our commitment to pursuing growth whilst keeping costs under control. We are going to boost our international performance levels, notably by integrating our Development, Regulatory Affairs and Sales & Marketing teams. This is a strategic choice for progressing our product portfolio, at a time when Loramyc® is being launched on the French market and has already been granted marketing approval in other European countries, in line with our stated objectives", commented Dominique Costantini, CEO.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and infectious disease markets.

In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical). For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
President and CEO
Tel.: +33 1 45 58 76 01

or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Dream Chip Technologies Presents First 22nm FD-SOI Silicon of New Automotive Driver Assistance SoC: Advanced driver assistance system (ADAS) computer vision SoC developed for European THINGS2DO project with working first silicon fabricated on GLOBALFOUNDRIES’ 22nm FD-SOI Platfor February 27th, 2017

Sandia use confined nanoparticles to improve hydrogen storage materials performance: Big changes from a small package for hydrogen storage February 25th, 2017

New nano approach could cut dose of leading HIV treatment in half February 24th, 2017

Atom-scale oxidation mechanism of nanoparticles helps develop anti-corrosion materials February 24th, 2017

Openings/New facilities/Groundbreaking/Expansion

GLOBALFOUNDRIES Expands to Meet Worldwide Customer Demand: Company invests for capacity growth in the United States, Germany, China and Singapore February 10th, 2017

Portable superconductivity systems for small motors: Cambridge University lab achieves a breakthrough for portable superconductivity systems that are applicable for small motors, health care and other uses February 8th, 2017

New Agricultural Research Center Debuts at UCF October 12th, 2016

Nexeon Establishes Base in Asia October 11th, 2016

Nanomedicine

New nano approach could cut dose of leading HIV treatment in half February 24th, 2017

Atomic force imaging used to study nematodes: KFU bionanotechnology lab (head - Dr. Rawil Fakhrullin) has obtained 3-D images of nematodes' cuticles February 23rd, 2017

Nominations Invited for $250,000 Kabiller Prize in Nanoscience: Major international prize recognizes a visionary nanotechnology researcher February 20th, 2017

Good vibrations help reveal molecular details: Rice University scientists combine disciplines to pinpoint small structures in unlabeled molecules February 15th, 2017

Announcements

Dream Chip Technologies Presents First 22nm FD-SOI Silicon of New Automotive Driver Assistance SoC: Advanced driver assistance system (ADAS) computer vision SoC developed for European THINGS2DO project with working first silicon fabricated on GLOBALFOUNDRIES’ 22nm FD-SOI Platfor February 27th, 2017

Sandia use confined nanoparticles to improve hydrogen storage materials performance: Big changes from a small package for hydrogen storage February 25th, 2017

New nano approach could cut dose of leading HIV treatment in half February 24th, 2017

Atom-scale oxidation mechanism of nanoparticles helps develop anti-corrosion materials February 24th, 2017

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project